CTI BioPharma

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

– Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – – ASH 2022 oral presentation featured new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis patients – – Management to host webcast and conference call at updated time today at 8:30 a.m. ET – SEATTLE , March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022.

CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results

SEATTLE , March 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will present a corporate overview at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET (7:30 a.m.

CTI BioPharma to Present at the 43rd Annual Cowen Health Care Conference

SEATTLE , Feb. 23, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its fourth quarter and full year 2022 financial results will be reported on Monday, March 6, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m.

CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023

SEATTLE , Feb. 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023: Guggenheim Partners 5th Annual Oncology Conference Wednesday, February 8, 2023 10:45 a.m. ET New York, NY SVB Securities Global Biopharma Conference Wednesday, February 15, 2023 3:40 p.m.

CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023

CTI BioPharma has reported a better-than-expected Q3 print of 18.5M, which is a 40% growth QoQ, and we expect this growth to continue reaching close to USD60M in FY2022. CTIC's Vonjo (Pacritinib) is a differentiated late-stage JAK2/IRAK4/FLT3/CSF1R inhibitor for the treatment of myelofibrosis in patients with severe thrombocytopenia (platelets

CTI BioPharma: Limited Cash Runway, But Better Than Expected Commercial Launch

SEATTLE , Jan. 5, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.

Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?

SEATTLE , Dec. 11, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH®) Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022. A new post-hoc data analysis from the Phase 3 PERSIST-2 trial of pacritinib, a novel JAK2/IRAK1 inhibitor approved by the U.S. Food and Drug Administration (FDA) for patients with myelofibrosis and severe thrombocytopenia (platelet count below 50 x 109/L), highlights pacritinib's potential anemia benefit in patients with myelofibrosis through its inhibition of Activin A receptor type 1 (ACVR1).

CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

SEATTLE , Nov. 30, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET. The conference will be held in a virtual meeting format.

CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit

SEATTLE , Nov. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York and London. Presentation details: Event: Stifel Healthcare ConferenceDate: Tuesday, November 15, 2022 Time: 1:15 p.m.

CTI BioPharma to Present at Upcoming November Conferences

CTI BioPharma Corp. (NASDAQ:CTIC ) Q3 2022 Results Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Adam Craig - President, Chief Executive Officer and Interim Chief Medical Officer James Fong - Executive Vice President and Chief Commercial Officer David Kirske - Executive Vice President and Chief Financial Officer Conference Call Participants Kelly Shi - Jefferies Kenneth Shields - SVB Securities Bert Hazlett - BTIG Benjamin Burnett - Stifel Reni Benjamin - JMP Securities Gil Blum - Needham & Company Thomas Flaten - Lake Street Capital Markets Operator Good afternoon. Thank you for standing by.

CTI BioPharma Corp. (CTIC) Q3 2022 Results - Earnings Call Transcript

CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.33% and 0.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates

– VONJO® (pacritinib) net product revenue of $18.2 million in the third quarter, a 48% increase compared to the second quarter – – Increase in sales reflects strong growth in new patient starts – – Oral presentation of new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis patients at ASH 2022 – – Management to host conference call today at 4:30 p.m. ET – SEATTLE , Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.

CTI BioPharma Reports Third Quarter 2022 Financial Results

SEATTLE , Nov. 3, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH®) Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022. The details of the oral presentation are as follows: Abstract Title: Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis Abstract Number: 628 Session Name: 634.

CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

Assertio Therapeutics Inc

Canopy Growth

Globalstar

Penny stocks to watch before November 2022 The post Best Penny Stocks To Buy? 4 To Watch Before November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 4 To Watch Before November

SEATTLE , Oct. 27, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2022 financial results on Monday, November 7, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m.

CTI BioPharma to Report Third Quarter 2022 Financial Results on November 7, 2022

Simultaneous double thumbs-ups from a pair of pundits gave it boost.

Why CTI BioPharma Stock Crushed the Market Today

Investors didn't exactly cheer the latest prognosticator move on the company's shares.

Why CTI BioPharma Stock Withered on Wednesday

SEATTLE , Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced two poster presentations from the Company's pacritinib program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, to be held in Houston, Texas and virtually September 28 – October 1, 2022.

CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting

CTIC announced its 2Q 2022 results on 8 August. With booked revenues coming in at $12.3 million for the quarter, revenues were above Street expectations. In my view, the 26% share price decline since the results is a reaction to BVF Partners (a major equity holder of the company) selling shares.

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

Woe betide any company that reports even a narrow bottom-line miss on quarterly results these days.

Why CTI BioPharma Stock Got Rocked on Tuesday

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

CTI BioPharma Corp. (NASDAQ:CTIC ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Adam Craig - Chief Executive Officer & President Jim Fong - Chief Commercial Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer Conference Call Participants Boris Peaker - Cowen Reni Benjamin - JMP Securities Ben Burnett - Stifel Thomas Flaten - Lake Street Capital Gil Blum - Needham & Company. Operator Hello and welcome to the CTI BioPharma Corporation 2Q 2022 Earnings Call.

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2022 Results - Earnings Call Transcript

– VONJO® (pacritinib) net product revenue of $12.3 million in the second quarter – – Management to host conference call today at 4:30 p.m. ET – SEATTLE , Aug. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2022.

CTI BioPharma Reports Second Quarter 2022 Financial Results

– Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer Summit – SEATTLE , Aug. 1, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m.

News for CTI BioPharma Stock (CTIC)